Almirall reported a nearly threefold increase in its first-quarter net profit, reaching 21.6 million euros, compared to the same period last year. The company's total sales rose 15% to 284.6 million euros, driven primarily by strong growth in its dermatology segment across Europe. Following these results, Almirall's shares surged between 7% and 8% in trading, and the company reaffirmed its full-year forecasts, citing its ability to continue offering impactful treatment alternatives. In contrast, Oryzon expanded its first-quarter losses to 1.7 million euros. Meanwhile, Grifols disclosed first-quarter revenues of 1.786 billion euros, marking a 7.4% increase, a performance closely monitored by investors. Additionally, the chronic pruritus market is projected to grow at a compound annual growth rate of 8.6% from 2020 to 2034, supported by new therapies such as Dupilumab.